Currently Viewing:
Newsroom
Currently Reading
Researchers Characterize Epidemiology of, Source of Infection in Febrile Neutropenia
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019
Adding COPD Screenings to Drug Clinic Appointments Yields Benefits for Patients
February 15, 2019 – Allison Inserro

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

Jaime Rosenberg
Pembrolizumab significantly improved overall survival (OS) and progression-free survival (PFS) as first-line treatment for squamous non–small cell lung cancer (NSCLC) in the pivotal phase 3 KEYNOTE-407 trial.
Pembrolizumab (Keytruda) has now demonstrated improved survival benefit in patients with advanced non–small cell lung cancer (NSCLC) in 5 phase 3 trials as Merck announced that the anti–PD-1 therapy, in combination with paclitaxel, as first-line treatment for metastatic squamous NSCLC, improved survival in the phase 3 KEYNOTE-407 trial.

Based on an interim analysis, the addition of pembrolizumab to carboplatin-paclitaxel or nab-paclitaxel demonstrated longer overall survival (OS) and progression-free survival (PFS) than chemotherapy alone, meeting the study’s dual primary end points.

The safety profile of the therapy in the combination was consistent with that previously observed in lung cancer, according to Merck.

“As first-line treatment, Keytruda in combination with traditional chemotherapy has not demonstrated an improved survival benefit, compared to chemotherapy alone, in metastatic lung cancer patients with squamous histology,” said Roger M. Perlmutter, MD, president, Merck, in a statement.

KEYNOTE-407 is a randomized, double-blind, placebo-controlled phase 3 trial including 560 untreated patients with metastatic squamous NSCLC. Patients had no previous systemic therapy for advanced disease. Primary endpoints were OS and PFS, and secondary endpoints included objective response rate, which was alpha-controlled in a cohort of the first 200 patients, and duration of response.

Data from the trial will be presented at the 2018 ASCO Meeting held in Chicago, Illinois, from June 1-5.

Last month, Merck announced that pembrolizumab monotherapy as first-line treatment in locally advanced or metastatic NSCLC met its primary endpoint of OS in the phase 3 KEYNOTE-042 trial. When compared with platinum-based chemotherapy in patients with a PD-L1 tumor proportion score of 1% or higher, the therapy significantly improved OS.

Shortly after, the pharmaceutical company announced that the FDA had granted priority review to their Biologics License Application for pembrolizumab in combination with pemetrexed (Alimta) and platinum chemotherapy as first-line treatment for patients with metastatic nonsquamous NSCLC. The acceptance was based on OS and PFS data from the phase 3 KEYNOTE-189 trial.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!